



Theranostic Radiopharmaceuticals: Current Status and Perspectives

Guest Editor:

**Prof. Dr. Tatjana P.
Stanojković**

Institute of Oncology and
Radiology of Serbia, Pasterova
14, 11000 Belgrade, Serbia

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Theranostics are nano-sized or molecular-level agents serving both diagnosis and therapy. Structurally, they are drug delivery systems integrated with molecular or targeted imaging agents. Theranostics are becoming popular because they are targeted therapeutics and can be used with no or minimal changes for diagnostic imaging to aid in precision medicine. Theranostics in nuclear medicine includes the use and application of two identical or very closely related radiopharmaceuticals for therapy and diagnosis. In oncology, tumor-specific substrates, receptor ligands, or drugs can serve as leads for theranostic development when labeled with specific radionuclides for imaging or therapy.

I am pleased to invite you to contribute a manuscript to this Special Issue, “Theranostic radiopharmaceuticals: current status and perspectives”. The goal of this Special Issue is to present the development of new drugs for theranostic applications, where imaging and therapeutic molecules should be parts of a single platform functionalized with various moieties for the specific recognition of molecular targets, imaging markers, and therapeutic compounds.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma